常染色体显性多囊肾病快速进展风险评估与疾病修饰治疗的特殊考量
本文综述了常染色体显性多囊肾病(ADPKD)进展至肾衰竭的风险评估方法,指出年龄校正的总肾体积(Mayo影像分类)是目前临床上最个体化的预测工具。托伐普坦已获批用于延缓快速进展风险患者的疾病进程,但各国对快速进展风险患者的选择标准差异很大,基于年龄、基线GFR、GFR斜率、基线TKV和TKV增长率等组合。
要点
- 年龄校正TKV(Mayo影像分类)是目前最个体化的ADPKD进展预测工具
- 托伐普坦已获批用于延缓快速进展风险患者的疾病进程
- 各国对快速进展风险患者的选择标准差异很大,基于年龄、GFR、TKV等多参数组合
核心结论
- 年龄校正TKV(Mayo影像分类)可估计每位患者独特的肾脏增长速率,提供目前临床可用的最个体化方法。
- 托伐普坦已获批用于延缓有快速进展风险患者的疾病进展。
研究设计与样本
- 综述,检索范围未在摘要中明确报告。
主要发现
- ADPKD是最常见的遗传性肾衰竭病因,占肾衰竭病例的5%-10%。
- 临床、遗传、环境、表观遗传和影像学因素均被研究作为ADPKD进展至肾衰竭的预测因子。
- 这些预后因素的复杂相互作用决定肾脏囊肿数量及其生长速率,进而影响总肾体积(TKV)。
关键数值与推荐
- 快速进展风险患者的选择标准各国差异很大,基于年龄、基线GFR、GFR斜率、基线TKV和TKV增长率等组合。
临床怎么用
- 临床应使用年龄校正TKV(Mayo影像分类)评估ADPKD患者肾脏增长速率以预测快速进展风险。
- 对快速进展风险患者可考虑早期启动托伐普坦等疾病修饰治疗以最大化延缓疾病进展的累积获益。
局限性
- 摘要未报告综述的检索范围及纳入研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause of kidney failure, accounting for 5%-10% of cases. Predicting which patients with ADPKD will progress rapidly to kidney failure is critical to assess the risk-benefit ratio of any intervention and to consider early initiation of long-term kidney protective measures that will maximize the cumulative benefit of slowing disease progression. Surrogate prognostic biomarkers are required to predict future decline in kidney function. Clinical, genetic, environmental, epigenetic, and radiologic factors have been studied as predictors of progression to kidney failure in ADPKD. A complex interaction of these prognostic factors determines the number of kidney cysts and their growth rates, which affect total kidney volume (TKV). Age-adjusted TKV, represented by the Mayo imaging classification, estimates each patient's unique rate of kidney growth and provides the most individualized approach available clinically so far. Tolvaptan has been approved to slow disease progression in patients at risk of rapidly progressive disease. Several other disease-modifying treatments are being studied in clinical trials. Selection criteria for patients at risk of rapid progression vary widely among countries and are based on a combination of age, baseline glomerular filtration rate (GFR), GFR slope, baseline TKV, and TKV rate of growth. This review details the approach in assessing the risk of disease progression in ADPKD and identifying patients who would benefit from long-term therapy with disease-modifying agents.
引用
- Chebib FT, Torres VE. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy. Am J Kidney Dis. 2021. PMID: 33705818. doi:10.1053/j.ajkd.2020.12.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。